Catheter‐Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN‐3 Trial
David E. Kandzari(Piedmont Atlanta Hospital), George L. Bakris(Pennsylvania State System of Higher Education), Joseph M. Massaro(Boston University), Deepak L. Bhatt(Mount Sinai Hospital), Murray Esler(Baker Heart and Diabetes Institute), John M. Flack(Southern Illinois University School of Medicine), Krishna J. Rocha‐Singh(St. John's Hospital), Raymond R. Townsend(University of Pennsylvania), Craig A. Straley(Medtronic (United States)), Barry T. Katzen(Baptist Hospital of Miami), Paul A. Sobotka(The Ohio State University), Martin B. Leon(Columbia University Irving Medical Center), William W. O’Neill(Henry Ford Health System), Manuela Negoita(Medtronic (United States)), Suzanne Oparil(University of Alabama at Birmingham)
Cited by 309
Related Papers
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
|Hypertension|2003|13.3k
General Cardiovascular Risk Profile for Use in Primary Care
|Circulation|2008|7.4k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k